The Drug Adherence and Treatment Effect of the Paliperidone Long Acting Injection.
10.4306/jknpa.2015.54.1.69
- Author:
Harin KIM
1
;
Jungsun LEE
;
Changyoon KIM
;
Yeonho JOO
Author Information
1. Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ljssmh@gmail.com
- Publication Type:Original Article
- Keywords:
Schizophrenia;
Paliperidone palmitate;
Long acting injection;
Medication adherence;
Treatment outcome
- MeSH:
Antipsychotic Agents;
Follow-Up Studies;
Humans;
Medication Adherence;
Psychotic Disorders;
Schizophrenia;
Treatment Outcome;
Paliperidone Palmitate
- From:Journal of Korean Neuropsychiatric Association
2015;54(1):69-75
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The aim of this study was to examine the drug adherence and treatment effect of the paliperidone long acting injection (LAI) in patients with schizophrenia or other psychotic disorders. METHODS: We reviewed the medical charts of patients who were prescribed paliperidone LAI from January 2010 to April 2014. Date of each injection, last observation, and first admission after use of the drug were obtained. Kaplan-Meier survival analysis was used for calculation of drug adherence. The dose of paliperidone LAI, concurrent oral antipsychotics, and anticholinergic agent was also obtained. Antipsychotics dose was calculated as olanzapine equivalent dose. RESULTS: The drug adherence of the paliperidone LAI on day 365 was 65%. The reasons for all cause discontinuation were follow-up loss, no effect, poor insight, rejection, extrapyramidal symptom, pain, etc. A total dose of 9.1 mg of oral antipsychotics was decreased, while the dose of anticholinergic agent was increased. CONCLUSION: The drug adherence of the paliperidone LAI was 65%, which was concordant with previous studies. The dose of concurrent oral antipsychotics was increased, while the dose of anticholinergic agent was decreased.
